BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 8809553)

  • 1. Factors affecting the immunogenicity of tetanus toxin fragment C expressed in Lactococcus lactis.
    Norton PM; Brown HW; Wells JM; Macpherson AM; Wilson PW; Le Page RW
    FEMS Immunol Med Microbiol; 1996 Jun; 14(2-3):167-77. PubMed ID: 8809553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lactococcus lactis: high-level expression of tetanus toxin fragment C and protection against lethal challenge.
    Wells JM; Wilson PW; Norton PM; Gasson MJ; Le Page RW
    Mol Microbiol; 1993 Jun; 8(6):1155-62. PubMed ID: 8361360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection against tetanus toxin after intragastric administration of two recombinant lactic acid bacteria: impact of strain viability and in vivo persistence.
    Grangette C; Müller-Alouf H; Geoffroy M; Goudercourt D; Turneer M; Mercenier A
    Vaccine; 2002 Sep; 20(27-28):3304-9. PubMed ID: 12213400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral vaccination of mice against tetanus with recombinant Lactococcus lactis.
    Robinson K; Chamberlain LM; Schofield KM; Wells JM; Le Page RW
    Nat Biotechnol; 1997 Jul; 15(7):653-7. PubMed ID: 9219268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protection against tetanus toxin in mice nasally immunized with recombinant Lactococcus lactis expressing tetanus toxin fragment C.
    Norton PM; Wells JM; Brown HW; Macpherson AM; Le Page RW
    Vaccine; 1997; 15(6-7):616-9. PubMed ID: 9178460
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sm14 of Schistosoma mansoni in fusion with tetanus toxin fragment C induces immunoprotection against tetanus and schistosomiasis in mice.
    Abreu PA; Miyasato PA; Vilar MM; Dias WO; Ho PL; Tendler M; Nascimento AL
    Infect Immun; 2004 Oct; 72(10):5931-7. PubMed ID: 15385496
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunization with recombinant Streptococcus gordonii expressing tetanus toxin fragment C confers protection from lethal challenge in mice.
    Medaglini D; Ciabattini A; Spinosa MR; Maggi T; Marcotte H; Oggioni MR; Pozzi G
    Vaccine; 2001 Feb; 19(15-16):1931-9. PubMed ID: 11228363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mucosal and cellular immune responses elicited by recombinant Lactococcus lactis strains expressing tetanus toxin fragment C.
    Robinson K; Chamberlain LM; Lopez MC; Rush CM; Marcotte H; Le Page RW; Wells JM
    Infect Immun; 2004 May; 72(5):2753-61. PubMed ID: 15102785
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of mice with poliovirus replicons expressing the C-fragment of tetanus toxin protects against lethal challenge with tetanus toxin.
    Porter DC; Wang J; Moldoveanu Z; McPherson S; Morrow CD
    Vaccine; 1997 Feb; 15(3):257-64. PubMed ID: 9139483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progress in the development of Lactococcus lactis as a recombinant mucosal vaccine delivery system.
    Norton PM; Le Page RW; Wells JM
    Folia Microbiol (Praha); 1995; 40(3):225-30. PubMed ID: 8919927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-expression of tetanus toxin fragment C in Escherichia coli with thioredoxin and its evaluation as an effective subunit vaccine candidate.
    Yu YZ; Gong ZW; Ma Y; Zhang SM; Zhu HQ; Wang WB; Du Y; Wang S; Yu WY; Sun ZW
    Vaccine; 2011 Aug; 29(35):5978-85. PubMed ID: 21718736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sublingually administered Bacillus subtilis cells expressing tetanus toxin C fragment induce protective systemic and mucosal antibodies against tetanus toxin in mice.
    Amuguni JH; Lee S; Kerstein KO; Brown DW; Belitsky BR; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
    Vaccine; 2011 Jun; 29(29-30):4778-84. PubMed ID: 21565244
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction of the ganglioside binding activity of the tetanus toxin HC fragment destroys immunogenicity: implications for development of novel tetanus vaccines.
    Qazi O; Sesardic D; Tierney R; Söderbäck Z; Crane D; Bolgiano B; Fairweather N
    Infect Immun; 2006 Aug; 74(8):4884-91. PubMed ID: 16861677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Gene cloning, optimized expression and immunogenicity evaluation of tetanus toxin fragment C].
    Wang MY; Zhang YN; Lei M; Zuo DM; Zhang LY; Chen ZL
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 May; 28(5):731-5. PubMed ID: 18504192
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Production and immunogenicity analysis of conformation-stable fragment-C mutant of tetanus toxin].
    Yu R; Hou L; Liu S; Yu C; Zhang X; Liu Y; Chen W
    Sheng Wu Gong Cheng Xue Bao; 2011 Feb; 27(2):226-32. PubMed ID: 21650047
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune response in mice following immunization with DNA encoding fragment C of tetanus toxin.
    Anderson R; Gao XM; Papakonstantinopoulou A; Roberts M; Dougan G
    Infect Immun; 1996 Aug; 64(8):3168-73. PubMed ID: 8757849
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the immune responses induced by local immunizations with recombinant Lactobacillus plantarum producing tetanus toxin fragment C in different cellular locations.
    Reveneau N; Geoffroy MC; Locht C; Chagnaud P; Mercenier A
    Vaccine; 2002 Mar; 20(13-14):1769-77. PubMed ID: 11906764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Instruments for oral disease-intervention strategies: recombinant Lactobacillus casei expressing tetanus toxin fragment C for vaccination or myelin proteins for oral tolerance induction in multiple sclerosis.
    Maassen CB; Laman JD; den Bak-Glashouwer MJ; Tielen FJ; van Holten-Neelen JC; Hoogteijling L; Antonissen C; Leer RJ; Pouwels PH; Boersma WJ; Shaw DM
    Vaccine; 1999 Apr; 17(17):2117-28. PubMed ID: 10367944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy, heat stability and safety of intranasally administered Bacillus subtilis spore or vegetative cell vaccines expressing tetanus toxin fragment C.
    Lee S; Belitsky BR; Brown DW; Brinker JP; Kerstein KO; Herrmann JE; Keusch GT; Sonenshein AL; Tzipori S
    Vaccine; 2010 Sep; 28(41):6658-65. PubMed ID: 20709005
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intranasal immunisation against tetanus with an attenuated Bordetella bronchiseptica vector expressing FrgC: improved immunogenicity using a Bvg-regulated promoter to express FrgC.
    Stevenson A; Roberts M
    Vaccine; 2004 Oct; 22(31-32):4300-5. PubMed ID: 15474722
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.